Skip to content

A Trial of RSL Versus WL for Malignant Breast Disease

A Randomized Single-Center Superiority Trial of Radioactive Seed Localization Versus Needle Localization for Malignant Breast Disease.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02522468
Acronym
BCS-RSL-001
Enrollment
400
Registered
2015-08-13
Start date
2015-07-24
Completion date
2021-02-23
Last updated
2022-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast- Female

Brief summary

The purpose of this randomized trial is to determine the superiority of utilizing radioactive seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable malignant lesions in patients undergoing breast conservation surgery (BCS).

Detailed description

Consented and eligible subjects will be randomized to either radioactive seed localization or wire localization and stratified by surgeon and invasive versus DCIS prior to localization. Subjects on both arms will undergo breast conservation surgery including surgical specimen removal. Specimens will be grossed according to standard of care procedures. Localization, breast conservation surgery, and post-operative appointments will follow standard of care guidelines. Surveys will be administered according to the study calendar to the radiologist, surgeon, pathologist, and subject for data collection.

Interventions

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Female * 20 to 99 years of age * Breast lesion necessitating image-guided excision * Unifocal disease * Breast-conservation candidate * Biopsy-proven malignant breast lesion including by not limited to invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ * Signed written informed consent document by the subject and/or a LAR

Exclusion criteria

* Male * Multifocal or multicentric disease * Receiving neoadjuvant chemotherapy * Pregnant or breastfeeding * Locally advanced disease * Breast conservation contraindication such as inability to receive whole breast radiation therapy, inability to tolerate localization procedure, inability to lay flat or prone for radiation, and undesirable tumor to breast ratio * Prior breast cancer on ipsilateral side * Unable or unwilling to adhere to post-localization instructions (e.g. timely seed removal)

Design outcomes

Primary

MeasureTime frameDescription
Surgical Resection Margins30 daysThe primary objective for this study will be the comparison between Radioactive Seed Localization (RSL) and Wire-Guided Localization (WL) based on negative margins in malignant breast disease. This is defined as no tumor on ink in invasive disease and greater than or equal to 2mm from the inked margin in non-invasive disease (DCIS).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026